Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts

Blood

Volumn 112, Issue 13, 2008, Pages 5074-5083

  Wakkach, Abdelilah ^a   Mansour, Anna ^a   Dacquin, Romain ^b   Coste, Emmanuel ^a   Jurdic, Pierre ^b   Carle, Georges F ^a   Blin Wakkach, Claudine ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INTERACTION; CELL SELECTION; CONTROLLED STUDY; DENDRITIC CELL; IMMUNE SYSTEM; IN VIVO STUDY; MICROENVIRONMENT; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; ANIMAL; BIOSYNTHESIS; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; STEM CELL NICHE; STROMA CELL; T LYMPHOCYTE;

ANIMALS; BONE MARROW; BONE RESORPTION; CELL DIFFERENTIATION; DENDRITIC CELLS; LYMPHOCYTE ACTIVATION; MICE; OSTEOCLASTS; RANK LIGAND; STEM CELL NICHE; STROMAL CELLS; T-LYMPHOCYTES;

EID: 58149398636     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-132787     Document Type: Article

References (52)

1. Arron J, Choi Y. Bone versus immune system. Nature. 2000;408:535-536.
2. Walsh MC, Kim N, Kadono Y, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol. 2006;24:33-63.
3. Stellon AJ, Davies A, Compston J, Williams R. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology. 1985;89:1078-1083.
4. Burnham JM, Leonard MB. Bone disease in pediatric rheumatologic disorders. Curr Rheumatol Rep. 2004;6:70-78.
5. Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol. 2003;15:857-864.
6. Haugeberg G, Orstavik RE, Kvien TK. Effects of rheumatoid arthritis on bone. Curr Opin Rheuma-tol. 2003;15:469-475.
7. Nakashima T, Wada T, Penninger JM. RANK-L and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol. 2003;15:280-287.
8. Cravens PD, Lipsky PE. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol Cell Biol. 2002;80:497-505.
9. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13:2412-2424.
10. Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med. 1997;186: 2075-2080.
11. Hume DA, Ross IL, Himes SR, Sasmono RT, Wells CA, Ravasi T. The mononuclear phagocyte system revisited. J Leukoc Biol. 2002;72:621-627.
12. Ardavin C. Dendritic cell heterogeneity: developmental plasticity and functional diversity. Semin Immunol. 2005;17:251-252.
13. Zhang M, Tang H, Guo Z, et al. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol. 2004;5: 1124-1133.
14. Coukos G, Benencia F, Buckanovich RJ, Conejo-Garcia JR. The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer. 2005;92: 1182-1187.
15. Rivollier A, Mazzorana M, Tebib J, et al. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood. 2004;104:4029-4037.
16. Alnaeeli M, Penninger JM, Teng YT Immune interactions with CD4+ T cells promote the development of functional osteoclasts from murine CD11c+ dendritic cells. J Immunol. 2006;177: 3314-3326.
17. Tolar J,Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med. 2004;351:2839-2849.
18. Scimeca JC, Franchi A, Trojani C, et al. The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone. 2000;26:207-213.
19. Seifert MF, Marks SC Jr. Morphological evidence of reduced bone resorption in the osteosclerotic (oc) mouse. Am J Anat. 1985;172:141-153.
20. Blin-Wakkach C, Wakkach A, Sexton PM, Rochet N, Carle GF. Hematological defects in the oc/oc mouse, a model of infantile malignant osteopetrosis. Leukemia. 2004;18:1505-1511.
21. Jung S, Unutmaz D, Wong P, et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity. 2002;17:211-220.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
23. Dacquin R, Davey RA, Laplace C, et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol. 2004;164:509-514.
24. Kamath AT, Pooley J, O'Keeffe MA, et al. The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol. 2000;165:6762-6770.
25. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity. 2003;18:605-617.
26. SudaT, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev. 1992;13: 66-80.
27. Roodman GD. Advances in bone biology: the osteoclast. Endocr Rev. 1996;17:308-332.
28. Miyamoto T, OhnedaO, Arai F, et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood. 2001;98:2544-2554.
29. Kim MS, Day CJ, Morrison NA. MCP-1 is induced by receptor activator of nuclear factor-κB ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem. 2005;280:16163-16169.
30. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANK-L signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3: 889-901.
31. Seifert MF, Marks SC Jr. Congenitally osteosclerotic (oc/oc) mice are resistant to cure by transplantation of bone marrow or spleen cells from normal littermates. Tissue Cell. 1987;19:29-37.
32. Frattini A, Blair HC, Sacco MG, et al. Rescue of ATPa3-deficient murine malignant osteopetrosis by hematopoietic stem cell transplantation in utero. Proc Natl Acad Sci USA. 2005;102: 14629-14634.
33. Johansson M, Jansson L, Ehinger M, Fasth A, Karlsson S, Richter J. Neonatal hematopoietic stem cell transplantation cures oc/oc mice from osteopetrosis. ExpHematol. 2006;34:242-249.
34. Banco R, Seifert MF, Marks SC Jr, McGuire JL. Rickets and osteopetrosis: the osteosclerotic (oc) mouse. Clin Orthop. 1985:238-246.
35. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med. 2005;11:76-81.
36. Cavanagh LL, Bonasio R, Mazo IB, et al. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. Nat Immunol. 2005;6:1029-1037.
37. Kong YY, Boyle WJ, Penninger JM. Osteoprote-gerin ligand: a regulator of immune responses and bone physiology. Immunol Today. 2000;21: 495-502.
38. Price PW, Cerny J. Characterization of CD4+ T cells in mouse bone marrow: I. Increased activated/memory phenotype and altered TCR Vbeta repertoire. Eur J Immunol. 1999;29:1051-1056.
39. Monteiro JP, Benjamin A, Costa ES, Barcinski MA, Bonomo A. Normal hematopoiesis is maintained by activated bone marrow CD4+ T cells. Blood. 2005;105:1484-1491.
40. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogen-esis. J Clin Invest. 1999;103:1345-1352.
41. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T-cell activation and bone destruction. J Exp Med. 2006;203:2673-2682.
42. Wong BR, Josien R, Choi Y TRANCE is aTNF family member that regulates dendritic cell and osteoclast function. J LeukocBiol. 1999;65:715-724.
43. Ronchese F, Hermans IF. Killing of dendritic cells: a life cut short or a purposeful death? J Exp Med. 2001;194:F23-F26.
44. da Costa CE, Annels NE, Faaij CM, Forsyth RG, Hogendoorn PC, Egeler RM. Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med. 2005;201:687-693.
45. Walsh MC, Choi Y Biology of the TRANCE axis. Cytokine Growth Factor Rev. 2003;14:251-263.
46. Josien R, Li HL, Ingulli E, et al. TRANCE, atumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med. 2000;191:495-502.
47. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304-309.
48. Ashcroft AJ, Cruickshank SM, Croucher PI, et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity. 2003;19:849-861.
49. Wakkach A, Augier S, Breittmayer JP, Blin-Wakkach C, Carle GF. Characterization of IL-10-secreting T cells derived from regulatory CD4 + CD25+ cells by theTIRC7 surface marker. J Immunol. 2008;180:6054-6063.
50. Ouyang W, Kolls JK, Zheng Y The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28:454-467.
51. Agarwal S, Misra R, Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol. 2008;35:515-519.
52. Pene J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated th17 lymphocytes. J Immunol. 2008;180:7423-7430.